张人和,韩双印.CAR-T细胞治疗实体瘤中靶点选择的研究进展[J].肿瘤学杂志,2019,25(11):930-935.
CAR-T细胞治疗实体瘤中靶点选择的研究进展
Research Advances in Target Selection of CAR-T Cells Therapy for Solid Tumors
投稿时间:2019-03-04  
DOI:10.11735/j.issn.1671-170X.2019.11.B001
中文关键词:  实体肿瘤  嵌合抗原受体修饰T细胞  靶点
英文关键词:solid tumors  chimeric antigen receptor-modified T cell  targets
基金项目:
作者单位
张人和 郑州大学人民医院 
韩双印 郑州大学人民医院 
摘要点击次数: 2061
全文下载次数: 439
中文摘要:
      摘 要:嵌合抗原受体修饰T 细胞(CAR-T)治疗是一种通过基因编辑表达跨膜嵌合抗原受体并重新导向T细胞特异性的基因治疗方法。近年来不断累积的临床数据证实了CAR-T细胞在血液系统肿瘤治疗中的安全性与有效性。实体肿瘤的生物学特性更为复杂,高肿瘤异质性等特点使CAR-T细胞的靶点选择充满挑战。研究者们正在不断探索实体肿瘤恶性表型所必需的合适靶点、寻找最佳抗原组合和治疗方案,目前已有一些实体肿瘤靶点在临床试验中展示了良好的结果。全文根据目前CAR-T细胞治疗实体肿瘤的临床试验结果,就实体瘤靶点选择的临床进展作一综述。
英文摘要:
      Abstract:Chimeric antigen receptor-modified T cell(CAR-T) therapy is a kind of gene therapy. CAR-T cells are prepared by gene editing,and expresses transmembrane chimeric antigen receptors redirecting T cell specificity. The accumulated clinical data in recent years has demonstrated the safety and efficacy of CAR-T cells in the treatment of hematological malignancies. The biological characteristics of solid tumors are more complex,and the high tumor heterogeneity leads to a more challenging antigenic target selection. Immunologists are exploring the appropriate targets indispensable for the malignant phenotype of solid tumors,finding the best antigen combination and therapeutic regimen, some of which have shown promising results in clinical trials. Based on the recent clinical trials of CAR-T therapy, this review summarizes and further discuss the advances in targets selection of CAR-T therapy for solid tumors.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器